Please wait a minute...
European Journal of Gynaecological Oncology  2020, Vol. 41 Issue (4): 609-616    DOI: 10.31083/j.ejgo.2020.04.5204
Original Research Previous articles | Next articles
Safety and efficacy of fertility-sparing surgery for an orthotopic xenograft model of epithelial ovarian cancer in nude mice
Gen-Hai Zhu1, *(), Kang Wang1, Lan Hong1, Xin-Hui Fu2, Fu-Jin Liu3, Hai-Yan Huang4
1Department of Gynecology, Hainan General Hospital, Haikou 570311, P. R. China
2Hainan Drug Research Institute, Haikou 570311, P. R. China
3Department of Pathology, Hainan General Hospital, Haikou 570311, P. R. China
4Medical Research Center, Hainan General Hospital, Haikou 570311, P. R. China
Download:  PDF(2611KB)  ( 209 ) Full text   ( 6 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
Objective: To analyze the safety of, and factors influencing, fertility-sparing surgery in nude a mouse model bearing an orthotopic xenograft of human epithelial ovarian cancer. Materials and Methods: Eight weeks post-xenograft transplantation, mice were split into five cohorts for different fertility-sparing surgeries to remove their tumours. All cohorts were observed for three months to analyse the effectiveness of the different surgical methods in terms of impact on occult cancer detection in the remaining ovarian tissues, and the effect of invasion types on the recurrence rate of ovarian tumor. Results: No obvious difference was found in the recurrence rate in groups subject to unilateral adnexectomy or ovarian-sparing local mass excision, when compared to the hysterectomy-bilateral adnexectomy group. The recurrence rate of tumors with pseudocapsule penetration and/or tumor dissection was higher than that with other invasion types and other surgery. The frequency of occult cancer detection in cancers displaying pseudocapsule and pseudocapsule invasion was significantly higher in those with tumor dissection when compared to those with ovarian-sparing local mass excision. Conclusions: Fertility-sparing surgery is not a factor influencing the prognosis of bilateral epithelial ovarian cancer. However, the invasion type of ovarian tumor exhibits an important role in fertility-sparing surgery; with tumors with pseudocapsule or pseudocapsule invasion being suitable for surgery, whereas tumors appearing with pseudocapsule penetration should be not be considered for this surgery. Ovarian-sparing local mass excision as a fertility-sparing surgery is safe and feasible for epithelial ovarian cancer at the experimental level, and now demands further pre-clinical validation in multi-center trials.
Key words:  Epithelial ovarian cancer      Fertility-sparing surgery      Neoplasm invasion type      Ovarian-sparing local mass excision     
Submitted:  29 October 2018      Accepted:  21 January 2019      Published:  15 August 2020     
Fund: 
ZDYF2017089/The Key Research and Development Program of Hainan Province, China
*Corresponding Author(s):  GEN-HAI ZHU     E-mail:  genhaizhu@163.com

Cite this article: 

Gen-Hai Zhu, Kang Wang, Lan Hong, Xin-Hui Fu, Fu-Jin Liu, Hai-Yan Huang. Safety and efficacy of fertility-sparing surgery for an orthotopic xenograft model of epithelial ovarian cancer in nude mice. European Journal of Gynaecological Oncology, 2020, 41(4): 609-616.

URL: 

https://ejgo.imrpress.com/EN/10.31083/j.ejgo.2020.04.5204     OR     https://ejgo.imrpress.com/EN/Y2020/V41/I4/609

[1] Emine Karabuk, Burak Karadag, Ceyda Karadag, M. Faruk Kose, M. Murat Naki, E. Nilufer Guler. The outcomes of fertility sparing surgery in epithelial ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 391-395.
[2] Chenchen Zhu, Hanyuan Liu, Zhen Shen, Yanhu Xie, Tianjiao Zhang, Björn Nashan, Dabao Wu, Ying Zhou. Treatment and survival outcomes from epithelial ovarian cancer in women aged 65 years or older[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 415-421.
[3] L. Nejković, J. Stulić, I. Rudić Biljić Erski, A. Ristić, R. Aničić, M. Vasiljević. Preserving fertility in patients with granulosa cell tumors of the ovary[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 462-464.
[4] Can Fang, Yan Zhao, Kezhen Li, Danhui Weng, Peng Wu, Gang Chen, Ding Ma, Juncheng Wei. Diabetes mellitus and epithelial ovarian cancer in Chinese women: a retrospective cohort study[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 260-264.
[5] T. Armeanu, R. Maftei, G. Simionescu, D. Nicolaiciuc, N. Plopa, B. Doroftei. Infertility and borderline malignant ovarian tumors: a case of successful pregnancy after fertility-preserving management of the disease[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 284-288.
[6] X.Z. Cheng, Z. Zhou, M.Y. Yang, Y.L. Cai, F. Deng, X.X. Chen. Prognostic factors for types I and II epithelial ovarian cancer in the elderly[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 7-15.
[7] M.W. Lui, P.P.C. Ip, E.Y.P. Lee, K.Y. Tse, H.Y.S. Ngan. Persistent low-grade endometrial stromal tumor during two consecutive pregnancies – a case report and review of literature[J]. European Journal of Gynaecological Oncology, 2019, 40(6): 1083-1086.
[8] V. Pažin, A. Dobrosavljevic, L. Nejkovic. Primary fallopian tube carcinoma – case report[J]. European Journal of Gynaecological Oncology, 2019, 40(1): 163-165.
[9] F. Atalay, K. Cetinkaya. Epithelial borderline ovarian tumors: clinicopathological characteristics, management options, and diagnostic role of intraoperative consultation[J]. European Journal of Gynaecological Oncology, 2018, 39(6): 988-991.
[10] Chen Mi, Cancan Zhang, Qi Zhang, Aiyun Xing. Increased expression of lncRNA HULC in human epithelial ovarian cancer and its biological functions[J]. European Journal of Gynaecological Oncology, 2018, 39(6): 992-996.
[11] Jing Zhao, Xue Dong, Qing-cui Liu, Qun Lu. Expression of plasma miR-106a in epithelial ovarian cancer and its diagnostic and prognostic significance[J]. European Journal of Gynaecological Oncology, 2018, 39(5): 769-772.
[12] Li-Yuan Guo, San-Yuan Zhang, Chen Chen, Hao-Xia Zeng, Feng-Yan Li, Qiu-Xiang Xu. Lentinan combined with cisplatin and paclitaxel in the treatment of patients with ovarian cancer with ascites[J]. European Journal of Gynaecological Oncology, 2018, 39(4): 615-620.
[13] K. Yao, C. Bian, L. Li, Y. Wu, X. Zhao. The clinical response of advanced epithelial ovarian cancer patients to neoadjuvant chemotherapy in China[J]. European Journal of Gynaecological Oncology, 2018, 39(3): 377-380.
[14] Jun Dai, Peishu Liu, Yangyun Liu, Wei Cai. An experimental study of cyclinD1 expression in human epithelial ovarian cancer cells[J]. European Journal of Gynaecological Oncology, 2018, 39(2): 247-252.
[15] B.D. de-la-Noval, M.D. Diestro Tejeda, L. Yébenes, I. Zapardiel, A. Hernández Gutiérrez, J. De-Santiago García. Recurrent endometriosis following tibolone hormone replacement therapy after mucinous ovarian carcinoma[J]. European Journal of Gynaecological Oncology, 2018, 39(2): 310-313.
No Suggested Reading articles found!